Sample Name
Sample Code
Sample Name
Sample Code
Sample Name
Sample Code
4
BIDU-SW
09888
5
JD HEALTH
06618
| (Q3)Sep 30, 2025 | (Q2)Jun 30, 2025 | (Q1)Mar 31, 2025 | (FY)Dec 31, 2024 | (Q4)Dec 31, 2024 | (Q3)Sep 30, 2024 | (Q2)Jun 30, 2024 | (Q1)Mar 31, 2024 | (FY)Dec 31, 2023 | (Q4)Dec 31, 2023 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Total revenue | 26.25%51.24B | 21.61%47.52B | 16.07%42.31B | 21.94%164.5B | 20.63%48.39B | 18.87%40.59B | 22.10%39.07B | 27.26%36.46B | 15.69%134.9B | 24.70%40.11B |
| Operating revenue | 25.89%50.55B | 21.33%46.93B | 15.88%41.8B | 21.62%162.78B | 20.34%47.87B | 18.62%40.16B | 21.74%38.68B | 26.85%36.08B | 15.58%133.84B | 24.38%39.78B |
| Cost of revenue | 24.83%9.21B | 16.19%8.49B | 14.04%7.57B | 16.19%30.16B | 14.87%8.84B | 18.76%7.38B | 22.93%7.31B | 8.71%6.64B | 2.81%25.96B | -7.69%7.7B |
| Gross profit | 26.56%42.04B | 22.86%39.03B | 16.53%34.74B | 23.31%134.34B | 22.00%39.55B | 18.89%33.21B | 21.91%31.76B | 32.29%29.82B | 19.25%108.94B | 36.04%32.42B |
| Operating expense | 35.53%21.5B | 9.86%18.58B | 7.44%17.19B | 4.45%64.96B | 0.94%16.18B | 11.81%15.86B | 1.52%16.92B | 4.49%16B | -0.36%62.19B | -8.02%16.03B |
| Selling and administrative expenses | 35.63%6.36B | -11.55%5.64B | -16.32%5.04B | -11.06%21.09B | -27.43%4B | -5.26%4.69B | -12.83%6.38B | 1.52%6.02B | -12.44%23.71B | -27.99%5.52B |
| -Selling and marketing expense | 0.82%2.85B | 9.48%2.98B | 7.53%2.76B | -7.76%11.35B | 0.43%3.24B | -1.91%2.82B | -13.73%2.72B | -15.77%2.56B | -19.40%12.3B | -29.47%3.23B |
| -General and administrative expense | 88.31%3.51B | -27.20%2.66B | -34.01%2.28B | -14.62%9.74B | -66.71%762M | -9.90%1.87B | -12.15%3.66B | 19.76%3.46B | -3.45%11.41B | -25.80%2.29B |
| Research and development costs | 35.49%15.14B | 22.82%12.94B | 21.77%12.15B | 14.01%43.87B | 15.81%12.18B | 20.95%11.18B | 12.77%10.54B | 6.36%9.98B | 8.90%38.48B | 7.63%10.52B |
| Operating profit | 18.36%20.54B | 37.68%20.44B | 27.04%17.56B | 48.40%69.38B | 42.60%23.36B | 26.20%17.35B | 58.08%14.85B | 91.20%13.82B | 61.52%46.75B | 156.04%16.38B |
| Net non-operating interest income (expenses) | 135.57%1.09B | -124.12%-103M | 15.98%595M | 89.17%1.97B | 18.39%573M | 24.59%461M | 828.26%427M | 258.74%513M | 2,470.45%1.04B | 257.65%484M |
| Non-operating interest income | -45.69%359M | -10.93%481M | 12.48%658M | 53.57%2.52B | 24.32%731M | 23.78%661M | 67.18%540M | 203.11%585M | 255.53%1.64B | 314.08%588M |
| Non-operating interest expense | 9.13%227M | 88.28%241M | 88.98%240M | 60.31%715M | 84.56%251M | 49.64%208M | 10.34%128M | 130.91%127M | 141.08%446M | 23.64%136M |
| Total other finance cost | -11,825.00%-954M | 2,386.67%343M | -221.82%-177M | -214.00%-171M | -190.63%-93M | -132.00%-8M | -109.32%-15M | -1,000.00%-55M | -53.13%150M | -109.44%-32M |
| Other net income (expenses) | 281.82%42M | 216.67%196M | 256.76%232M | -88.52%-690M | -531.15%-385M | 111.22%11M | -15.86%-168M | -134.92%-148M | -351.85%-366M | -207.02%-61M |
| Gain on sale of security | 281.82%42M | 216.67%196M | 256.76%232M | -88.52%-690M | -531.15%-385M | 111.22%11M | -15.86%-168M | -134.92%-148M | -351.85%-366M | -207.02%-61M |
| Income before tax | 21.55%21.66B | 35.93%20.53B | 29.61%18.38B | 48.99%70.66B | 40.13%23.55B | 27.12%17.82B | 62.55%15.11B | 94.10%14.18B | 64.57%47.43B | 173.33%16.81B |
| Income tax | 788.19%18.95B | 33.88%2.2B | -4.19%1.74B | -0.32%8.3B | -2.72%2.71B | -12.43%2.13B | 9.04%1.64B | 13.52%1.81B | 48.25%8.33B | 86.50%2.79B |
| Earnings from equity interest net of tax | ||||||||||
| Net income | -82.73%2.71B | 36.18%18.34B | 34.56%16.64B | 59.50%62.36B | 48.66%20.84B | 35.44%15.69B | 72.89%13.47B | 116.66%12.37B | 68.53%39.1B | 201.25%14.02B |
| Net income continuous operations | -82.73%2.71B | 36.18%18.34B | 34.56%16.64B | 59.50%62.36B | 48.66%20.84B | 35.44%15.69B | 72.89%13.47B | 116.66%12.37B | 68.53%39.1B | 201.25%14.02B |
| Noncontrolling interests | ||||||||||
| Net income attributable to the company | -82.73%2.71B | 36.18%18.34B | 34.56%16.64B | 59.50%62.36B | 48.66%20.84B | 35.44%15.69B | 72.89%13.47B | 116.66%12.37B | 68.53%39.1B | 201.25%14.02B |
| Preferred stock dividends | ||||||||||
| Other under preferred stock dividend | ||||||||||
| Net income attributable to common stockholders | -82.73%2.71B | 36.18%18.34B | 34.56%16.64B | 59.50%62.36B | 48.66%20.84B | 35.44%15.69B | 72.89%13.47B | 116.66%12.37B | 68.53%39.1B | 201.25%14.02B |
| Diluted earnings per share | -82.58%0.0439 | 37.10%0.2958 | 35.60%0.2678 | 62.01%1 | 50.92%0.3348 | 37.78%0.2519 | 75.25%0.2158 | 119.91%0.1975 | 76.01%0.6172 | 210.23%0.2219 |
| Basic earnings per share | -82.59%0.0427 | 38.37%0.2901 | 36.52%0.2613 | 60.46%0.9695 | 50.47%0.3259 | 37.36%0.245 | 73.15%0.2097 | 114.09%0.1914 | 73.11%0.6042 | 202.84%0.2166 |
| Dividend per share | 1.84%0.0207 | 4.82%0.0211 | -3.66%0.02 | 0.0806 | 0.0194 | 0.0203 | 0.0202 | 0.0207 | ||
| Accounting Standards | US-GAAP | US-GAAP | US-GAAP | US-GAAP | US-GAAP | US-GAAP | US-GAAP | US-GAAP | US-GAAP | US-GAAP |
| Audit Opinions | -- | -- | -- | Unqualified Opinion | -- | -- | -- | -- | Unqualified Opinion | -- |
FY: Financial Year. Refers to the 10-K file disclosed by the listed company to the SEC.
Q: Quarter. Refers to the 10-Q file disclosed by the listed company to the SEC. Q1, Q2, Q3, and Q4 are quarterly reports each with a span of 3 months; Q6 and Q9 are cumulative reports, with Q6 including 6 months and Q9 9 months.